Relugolix: A Novel Gonadotropin-Releasing Hormone Antagonist for Prostate Cancer

Simple item page
dc.contributor.authorBabu, Merinen_US
dc.contributor.authorPavithran, Keechilaten_US
dc.date.accessioned2023-06-17T07:10:54Z
dc.date.available2023-06-17T07:10:54Z
dc.date.issued2021-03
dc.description.abstractAndrogen deprivation therapy (ADT) is currently the mainstay of treatment for advanced prostate cancer. The peptide formulations of gonadotropin-releasing hormone (GnRH) antagonists need to be given subcutaneously every month. This led to the development of an oral, nonpeptide GnRH antagonist formulation relugolix which promptly lowers the levels of testosterone, luteinizing hormone, and follicular-stimulating hormone. On December 18, 2020, the US Food and Drug Administration approved relugolix for the treatment of adult advanced prostate cancer. The recommended loading dose of 360 mg on the 1st day of treatment, followed by 120 mg once daily orally, approximately the same time each day. The maximum plasma concentration (Tmax) is obtained within 2.25 h and is metabolized to a major extent by CYP3A mediated mechanism. Hot flushes, musculoskeletal pain, and fatigue are some of its common adverse effects. High rates of testosterone suppression with a limited adverse event profile make it an ideal therapy for the treatment of advanced prostate cancer.en_US
dc.identifier.affiliationsDepartment of Pharmacology, Amrita School of Pharmacy, Amrita Vishwa Vidyapeethamen_US
dc.identifier.affiliationsDepartment of Medical Oncology, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Kochi, Kerala, Indiaen_US
dc.identifier.citationBabu Merin, Pavithran Keechilat. Relugolix: A Novel Gonadotropin-Releasing Hormone Antagonist for Prostate Cancer. Journal of Pharmacology and Pharmacotherapeutics . 2021 Mar; 12(1): 26-28en_US
dc.identifier.issn0976-500X
dc.identifier.issn0976-5018
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/215997
dc.languageenen_US
dc.publisherWolters Kluwer – Medknowen_US
dc.relation.issuenumber1en_US
dc.relation.volume12en_US
dc.source.urihttps://doi.org/10.4103/jpp.jpp_170_20en_US
dc.subjectAndrogen deprivation therapyen_US
dc.subjectdegarelixen_US
dc.subjectfollicular-stimulating hormoneen_US
dc.subjectgonadotropin antagonisten_US
dc.subjectluteinizing hormoneen_US
dc.titleRelugolix: A Novel Gonadotropin-Releasing Hormone Antagonist for Prostate Canceren_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
JPP2021v12n1p26.pdf
Size:
346.93 KB
Format:
Adobe Portable Document Format
Download
Collections
Journal of Pharmacology and Pharmacotherapeutics